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Influenza viruses collected from regions of Asia, Africa and Oceania
between 2009 and 2012 were tested for their susceptibility to two
new neuraminidase inhibitors, peramivir and laninamivir. All
viruses tested had normal laninamivir inhibition. However, 32%
(19/599) of A(H1N1)pdm09 viruses had highly reduced peramivir
inhibition (due to H275Y NA mutation) and <1% (6/1238) of
influenza B viruses had reduced or highly reduced peramivir
inhibition, with single occurrence of variants containing I221T,
A245T, K360E, A395E, D432G and a combined G145R+Y142H
mutation. These data demonstrate that despite an increase in H275Y
variants in 2011, there was no marked change in the frequency of
peramivir- or laninamivir-resistant variants following the market
release of the drugs in Japan in 2010.
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Introduction
Currently, the neuraminidase inhibitors (NAIs) are the only
class of antivirals that are effective against circulating
influenza A and B viruses due to widespread resistance
against the older adamantane class of drugs.1 Two NAIs,
orally administered oseltamivir (Tamiflu) and inhaled
zanamivir (Relenza), have been licensed in many countries
since 1999. In 2010, two new NAIs, peramivir (Rapiacta)
and laninamivir (Inavir), were licensed in Japan.2 Peramivir
has also been licensed in South Korea3 and most recently in
China, as a response to concerns of A(H7N9) avian
influenza.4 Peramivir is delivered intravenously and therefore
is well suited to treating severely ill patients who may be
unable to use oral or inhaled formulations.5 Laninamivir
octanoate, a prodrug of laninamivir, is administered by
inhalation (in a powdered form) and is quickly converted
into its active form in the lungs.6 However, compared with
oseltamivir and zanamivir, which are administered twice
daily for 5 days, laninamivir is long-acting, requiring only a
single administration for retention of the drug for at least five
days.7 During 2011–2012, laninamivir was the largest selling
NA inhibitor in Japan.8 As with any new antiviral agents that
are released to the market, it is important to monitor
circulating influenza strains for the development of resistance
to both peramivir and laninamivir.9–11 This is particularly
pertinent given the widespread resistance to the NAI
oseltamivir that occurred in seasonal A(H1N1) viruses in
2008.12,13 Here, we evaluate the peramivir and laninamivir
susceptibility of influenza A and B viruses circulating in parts
of Asia, Africa and Oceania between 2009 and 2012, a time
frame that spans pre- and post-market launch of these drugs
in Japan and South Korea.
Sample selection and classification criteria
Approximately 2500 influenza A and 1238 influenza B viruses
collected from 19 countries and territories in Asia, Africa and
Oceania via the WHO Global Influenza Surveillance and
Response System (GISRS) between 2009 and 2012, were
screened for peramivir and laninamivir susceptibility. Viruses
were received from the following countries and territories:
Australia (2492), Brunei (5), Cambodia (164), Fiji (23),
Hong Kong (4), Kenya (8), Macau (SAR, China) (101),
Malaysia (44), New Caledonia (9), New Zealand (457),
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Solomon Islands (1), South Africa (17), South Korea (10), Sri
Lanka (27), Taiwan (6) and Thailand (92). Peramivir
susceptibility and laninamivir susceptibility were assessed
using a functional fluorescence-based NA inhibition assay as
described by Hurt et al.14 Sequence analysis was conducted
using standard methods.
In line with the recommendations implemented by the
WHO GISRS Expert Committee for Antiviral Resistance in
Influenza, virus susceptibility was classified based on fold
differences compared with the respective NA inhibitor
median IC50 of the matching subtype/type.
15
Peramivir susceptibility
The peramivir susceptibility of 2548 influenza A and 1238
influenza B viruses was tested, of which 968% (580/599) of A
(H1N1)pdm09 and 994% (1231/1238) of influenza B viruses
demonstrated normal peramivir inhibition, while all A
(H3N2) isolates (n = 1949) exhibited normal peramivir
inhibition. The mean (standard deviation) peramivir IC50
of the influenza B viruses with normal inhibition was
074  033 nM, four-fold higher than the mean IC50 of the
influenza A(H1N1)pdm09 or A(H3N2) viruses (Table 1). In
addition, there was no significant difference in the median
peramivir IC50s of B Victoria compared with B Yamagata
lineage viruses exhibiting normal inhibition.
Nineteen A(H1N1)pdm09 viruses (19/599, 32%) had
highly reduced peramivir inhibition (Figure 1), with a mean
IC50 value of 313  103 nM, 241-fold above the median
peramivir IC50 of A(H1N1)pdm09 viruses with normal
inhibition. Genetic analysis of these viruses revealed that they
all contained the H275Y NA substitution (N1 numbering,
codon 274 in N2 numbering), a mutation known to confer
highly reduced oseltamivir inhibition.12 Forty-two per cent
(8/19) of the H275Y variants detected were from a cluster of
cases in Australia in 2011,16 but additional strains were also
detected in other regions of Australia (2009; 2011; 2012,
n = 5) and from countries such as Thailand (2010, n = 1),
Singapore (2010, n = 3), Brunei (2011, n = 1) and Philip-
pines (2011, n = 1) where peramivir and laninamivir are not
licensed for use.
Six influenza B virus isolates were identified as having
reduced or highly reduced peramivir inhibition (Figure 1,
Table 2). The following influenza B residues are numbered
based on straight influenza B NA amino acid numbering
starting from the first methionine residue, GISAID accession
numbers for sequences of the variant viruses are listed in
Table 2. B/Malaysia/210/2012 contained two novel NA
mutations Y142H and G145R, with the resulting isolate
demonstrating a 487-fold increase in peramivir IC50
(Table 2). Y142H is located on the surface of the NA active
site and could indirectly affect the binding pocket scaffold
loop region including G145R (Figure 2). This may explain
how G145R together with Y142H have a strong additive
inhibitory effect. Other novel substitutions located in a
framework residue (D432G) and outside the active site
(K360E and A395E) (Figure 2) were also identified in three
influenza B viruses from Thailand and Malaysia with reduced
or highly reduced inhibition. B/Bangkok/29/2012, which
contained A395E, had a minor five-fold increase in peramivir
IC50, while B/Malaysia/283/2012 and B/Malaysia/221/2012,
which contained K360E and D432G NA mutations, respec-
tively, had 165- and 41-fold increases in peramivir IC50
(Table 2). All five of these B variants had normal laninam-
ivir, oseltamivir and zanamivir inhibition, apart from B/
Bangkok/29/2012 (A395E NA mutation) which had a five-
fold increase in oseltamivir IC50. The final two B strains with
reduced or highly reduced peramivir inhibition, B/Waikato/
21/2011 and B/Wellington/39/2011, have previously been
reported to have reduced inhibition to zanamivir and/or
oseltamivir.17 B/Waikato/21/2011 contained an A245T NA
mutation and demonstrated a five-fold increase in peramivir
NA inhibitors A(H1N1)pdm09 IC50 (nM) A(H3N2) IC50 (nM) B IC50 (nM)
Peramivir
No. tested, n 580 1949 1231
Median (p25, p75) 013 (010, 024) 020 (015, 027) 068 (050, 090)
Mean  SD 017  010 018  008 074  033
Laninamivir
No. tested, n 511 1950 1238
Median (p25, p75) 022 (019, 030) 060 (045, 080) 237 (192, 300)
Mean  SD 027  005 062  005 326  026
*To determine the overall median and mean peramivir and laninamivir IC50 of influenza viruses
with normal inhibition, the median for all viruses tested in 2009, 2010, 2011 and 2012 was initially
calculated. Viruses with IC50 10-fold or more (or five-fold or more for influenza B) above the
median were then removed from the data set. The final median and mean IC50 of normal inhibition
viruses were then recalculate and are displayed in Table 1.
Table 1. Overall median and mean
peramivir and laninamivir IC50 of influenza
viruses with normal inhibition*
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IC50, while B/Wellington/39/2011 contained an I221T muta-
tion which resulted in a 43-fold increase in peramivir IC50
(Table 2). Variant viruses with either an I221T or I221V NA
mutation have also been reported in a number of B viruses
from USA and China.18,19 Compared with wild-type viruses,
the I221T variant reported here had a much greater increase
in peramivir IC50 (43-fold), than reported for the I221V
variants from the USA, which exhibited an eight-fold
increase.19 I221T and A245T are both located near the
substrate binding site of the NA (Figure 2). Apart from
reductions in peramivir sensitivity, the I221T B variant also
demonstrated reduced oseltamivir inhibition17, while the
A245T mutation was found to affect sensitivity to three of the
four NA inhibitors, oseltamivir (20-fold reduction), zanam-
ivir (32-fold reduction) and peramivir (five-fold reduction),
even though the residue is not located within the NA active
site. The original clinical specimens of many of these isolates
were not available to the WHO Collaborating Centre for
Reference and Research on Influenza, Melbourne, for
sequence analysis (details listed in Table 2) as clinical
specimens are often discarded by submitting laboratories









Figure 1. Box-and-whisker plots comparing the distribution of (A) peramivir IC50 and (B) laninamivir IC50 values (log10 transformed) of A(H1N1)pdm09,
A(H3N2) and influenza B viruses from 2009 to 2012. The boxes represent the 25th to 75th percentiles, with horizontal lines within each box representing
the median IC50 values. The whiskers represent the highest and the lowest values situated within the 15 IQR plus 75th percentile and the 15 IQR minus
25th percentile regions. The dashed lines define the regions “normal inhibition” (NI); “reduced inhibition” (RI); and “highly reduced inhibition” (HRI).
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investigate whether the mutations had arisen during cell
culture, as has been the case for some NAI-resistant variants
previously reported.20
Laninamivir susceptibility
All 511 A(H1N1)pdm09, 1950 A(H3N2) viruses and 1238
influenza B had IC50 values that fell within the normal
laninamivir inhibition range. The mean (standard devia-
tion) laninamivir IC50 values for A(H1N1)pdm09 and A
(H3N2) viruses were 027  005 nM and 062  005 nM,
respectively. The mean (standard deviation) laninami-
vir IC50 for the 1238 influenza B isolates was 326  026 nM,
5–12-fold higher than the mean IC50 of the influenza A
(H1N1)pdm09 and A(H3N2) viruses. Again, no difference
was observed between the laninamivir susceptibility of the
two B lineages.
Conclusion
Although peramivir and laninamivir are currently only
licensed in Japan (and in the case of peramivir, also in
South Korea and China), approval in other countries is likely
to follow as late-phase clinical trials are completed. Of the
viruses analysed, none of the A(H1N1)pdm09, A(H3N2) and
influenza B viruses had reduced or highly reduced laninam-
ivir inhibition, while a small number of A(H1N1)pdm09
(32%) and B (05%) viruses had reduced peramivir suscep-
tibility. Of the viruses considered to have normal inhibition,
the mean and median values IC50 for peramivir were lower
than those for laninamivir for all of the three influenza types/
subtypes tested. The clinical implications of these differences,
and for the H275Y variant viruses with highly reduced
peramivir inhibition, are currently unknown and therefore
require further study. However, given that the high concen-
tration of peramivir achieved in the blood following intra-
venous administration21, it could be expected that the H275Y
and influenza B variants detected here would be inhibited.
However, clinical studies have suggested that peramivir is less
effective when treating H275Y variant viruses compared with
viruses with normal inhibition.22
Table 2. Influenza B viruses with reduced or highly reduced peramivir inhibition
Designation
GISAID






B/Waikato/21/2011 EPI_ISL_118616 B/Victoria A245T*** Reduced inhibition 348  114 (5) 730  135 (3)
B/Bangkok/29/2012 EPI_ISL_134483 B/Victoria A395E*** Reduced inhibition 373  157 (5) 381  047
B/Malaysia/221/2012 EPI_ISL_122586 B/Victoria D432G*** Reduced inhibition 2801  875 (41) 114  033
B/Wellington/39/2011 EPI_ISL_118617 B/Victoria I221T** Reduced inhibition 2935  865 (43) 253  022
B/Malaysia/283/2012 EPI_ISL_128716 B/Victoria K360E*** Highly reduced
inhibition
11209  3794 (165) 197  057
B/Malaysia/210/2012 EPI_ISL_128715 B/Victoria G145R***; Y142H*** Highly reduced
inhibition
33137  26220 (487) 326  106
*Mean IC50  SD (nM), each virus tested in three independent assays.
**Detected in clinical specimen and virus isolate.
***Clinical specimen not available.
†Fold difference based on comparison with the influenza B median IC50 of viruses with normal inhibition as displayed in Table 1 (only fold difference
>3 are listed).
Figure 2. Neuraminidase residue substitutions associated with highly
reduced or reduced peramivir susceptibility. The structure is from B/Perth/
211/2001 (PDB ID: 3K37, \www.rcsb.org) and visualized with YASARA
(\www.yasara.org) Peramivir is represented in magenta and laninamivir
(superimposed from PDB ID: 3TIA) in yellow, the mutations are red with
wild-type residue shown.
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This study has found no evidence of widespread emer-
gence of viruses with highly reduced peramivir or laninam-
ivir inhibition since the market launch in 2010, although the
increased number of community cases of A(H1N1)pdm09
viruses with H275Y NA mutation in 2011 (which had highly
reduced peramivir inhibition) was concerning. However, a
limitation of this study is that the majority of the viruses
tested were from regions where peramivir or laninamivir has
not been approved for use. Therefore, although our data
suggest that peramivir- and laninamivir-resistant viruses are
not spreading from regions where the drugs are being used,
further studies are required to assess the susceptibility of
Japanese and South Korean viruses collected from both drug-
treated and untreated patients.
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